View Future GrowthS.C. Sintofarm 過去の業績過去 基準チェック /26S.C. Sintofarmの収益は年間平均-13.2%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 増加しています。収益は年間8.8% 8.1%割合で 増加しています。 S.C. Sintofarmの自己資本利益率は3%であり、純利益率は2.5%です。主要情報-13.16%収益成長率-13.16%EPS成長率Pharmaceuticals 業界の成長12.39%収益成長率8.07%株主資本利益率3.04%ネット・マージン2.54%次回の業績アップデート31 Aug 2026最近の業績更新Reported Earnings • Mar 25Full year 2025 earnings releasedFull year 2025 results: Revenue: RON12.9m (up 4.5% from FY 2024). Net income: RON327.0k (up RON556.4k from FY 2024). Profit margin: 2.5% (up from net loss in FY 2024).Reported Earnings • Apr 27Full year 2023 earnings releasedFull year 2023 results: Revenue: RON11.5m (up 9.9% from FY 2022). Net income: RON487.2k (down 30% from FY 2022). Profit margin: 4.2% (down from 6.6% in FY 2022). The decrease in margin was driven by higher expenses.すべての更新を表示Recent updatesBoard Change • Aug 04No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. No independent directors (3 non-independent directors). Director Berezetcki Patricia was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Jul 17No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. No independent directors (3 non-independent directors). Director Berezetcki Patricia was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Jul 02No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. No independent directors (3 non-independent directors). Director Berezetcki Patricia was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. No independent directors (3 non-independent directors). Director Berezetcki Patricia was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Apr 14No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. No independent directors (3 non-independent directors). Director Berezetcki Patricia was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Mar 25Full year 2025 earnings releasedFull year 2025 results: Revenue: RON12.9m (up 4.5% from FY 2024). Net income: RON327.0k (up RON556.4k from FY 2024). Profit margin: 2.5% (up from net loss in FY 2024).お知らせ • Mar 19S.C. Sintofarm S.A., Annual General Meeting, Apr 22, 2026S.C. Sintofarm S.A., Annual General Meeting, Apr 22, 2026.New Risk • Mar 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 8.0% per year over the past 5 years. Market cap is less than US$10m (RON38.4m market cap, or US$8.68m). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (RON13m revenue, or US$2.9m).Board Change • Feb 11No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. No independent directors (3 non-independent directors). Director Berezetcki Patricia was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Jan 12No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. No independent directors (3 non-independent directors). Director Berezetcki Patricia was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Mar 13S.C. Sintofarm S.A., Annual General Meeting, Apr 24, 2025S.C. Sintofarm S.A., Annual General Meeting, Apr 24, 2025.Valuation Update With 7 Day Price Move • Feb 07Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to RON4.30, the stock trades at a trailing P/E ratio of 24x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 23% over the past year.Board Change • Jan 31No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Berezetcki Patricia was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Oct 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Berezetcki Patricia was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Jun 14Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to RON4.80, the stock trades at a trailing P/E ratio of 38x. Average trailing P/E is 25x in the Pharmaceuticals industry in Europe.Reported Earnings • Apr 27Full year 2023 earnings releasedFull year 2023 results: Revenue: RON11.5m (up 9.9% from FY 2022). Net income: RON487.2k (down 30% from FY 2022). Profit margin: 4.2% (down from 6.6% in FY 2022). The decrease in margin was driven by higher expenses.Board Change • Apr 22No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 3 highly experienced directors. No independent directors (3 non-independent directors). Director Beja Antonio was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.収支内訳S.C. Sintofarm の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史BVB:SINT 収益、費用、利益 ( )RON Millions日付収益収益G+A経費研究開発費31 Dec 251308030 Sep 251308030 Jun 251308031 Mar 251308001 Jan 251208001 Oct 241208030 Jun 241217031 Mar 241217001 Jan 241107001 Oct 231116030 Jun 231115031 Mar 231115001 Jan 231014001 Oct 221012030 Jun 221010031 Mar 221000031 Dec 211000030 Sep 21900030 Jun 21900031 Mar 21900031 Dec 20900030 Sep 20902030 Jun 20803031 Mar 20803001 Jan 20803001 Oct 19703030 Jun 197-13031 Mar 196-13001 Jan 196-12001 Oct 186-12030 Jun 186-12031 Mar 186-12001 Jan 186-12001 Oct 17602030 Jun 17602031 Mar 17602001 Jan 17602001 Oct 16602030 Jun 16712031 Mar 16712001 Jan 16612030 Sep 156120質の高い収益: SINTは 高品質の収益 を持っています。利益率の向上: SINT過去に利益を上げました。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: SINTの収益は過去 5 年間で年間13.2%減少しました。成長の加速: SINTは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。収益対業界: SINT昨年収益を上げたため、昨年の収益成長をPharmaceuticals業界 ( 14.5% ) と比較することは困難です。株主資本利益率高いROE: SINTの 自己資本利益率 ( 3% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/07 10:32終値2026/08/06 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋S.C. Sintofarm S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Mar 25Full year 2025 earnings releasedFull year 2025 results: Revenue: RON12.9m (up 4.5% from FY 2024). Net income: RON327.0k (up RON556.4k from FY 2024). Profit margin: 2.5% (up from net loss in FY 2024).
Reported Earnings • Apr 27Full year 2023 earnings releasedFull year 2023 results: Revenue: RON11.5m (up 9.9% from FY 2022). Net income: RON487.2k (down 30% from FY 2022). Profit margin: 4.2% (down from 6.6% in FY 2022). The decrease in margin was driven by higher expenses.
Board Change • Aug 04No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. No independent directors (3 non-independent directors). Director Berezetcki Patricia was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Jul 17No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. No independent directors (3 non-independent directors). Director Berezetcki Patricia was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Jul 02No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. No independent directors (3 non-independent directors). Director Berezetcki Patricia was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. No independent directors (3 non-independent directors). Director Berezetcki Patricia was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Apr 14No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. No independent directors (3 non-independent directors). Director Berezetcki Patricia was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Mar 25Full year 2025 earnings releasedFull year 2025 results: Revenue: RON12.9m (up 4.5% from FY 2024). Net income: RON327.0k (up RON556.4k from FY 2024). Profit margin: 2.5% (up from net loss in FY 2024).
お知らせ • Mar 19S.C. Sintofarm S.A., Annual General Meeting, Apr 22, 2026S.C. Sintofarm S.A., Annual General Meeting, Apr 22, 2026.
New Risk • Mar 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 8.0% per year over the past 5 years. Market cap is less than US$10m (RON38.4m market cap, or US$8.68m). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (RON13m revenue, or US$2.9m).
Board Change • Feb 11No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. No independent directors (3 non-independent directors). Director Berezetcki Patricia was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Jan 12No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. No independent directors (3 non-independent directors). Director Berezetcki Patricia was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Mar 13S.C. Sintofarm S.A., Annual General Meeting, Apr 24, 2025S.C. Sintofarm S.A., Annual General Meeting, Apr 24, 2025.
Valuation Update With 7 Day Price Move • Feb 07Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to RON4.30, the stock trades at a trailing P/E ratio of 24x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 23% over the past year.
Board Change • Jan 31No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Berezetcki Patricia was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Oct 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Berezetcki Patricia was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Jun 14Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to RON4.80, the stock trades at a trailing P/E ratio of 38x. Average trailing P/E is 25x in the Pharmaceuticals industry in Europe.
Reported Earnings • Apr 27Full year 2023 earnings releasedFull year 2023 results: Revenue: RON11.5m (up 9.9% from FY 2022). Net income: RON487.2k (down 30% from FY 2022). Profit margin: 4.2% (down from 6.6% in FY 2022). The decrease in margin was driven by higher expenses.
Board Change • Apr 22No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 3 highly experienced directors. No independent directors (3 non-independent directors). Director Beja Antonio was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.